Deciphera Pharmaceuticals

$47.00
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.23 (-0.49%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell DCPH and other stocks, options, and ETFs commission-free!

About DCPH

Deciphera Pharmaceuticals, Inc. engages in discovering, developing, and delivering important new medicines to patients for the treatment of cancer. The firm designs a drug candidate, DCC-2618, to inhibit the full spectrum of mutant or amplified KIT and PDGFRa kinases that drive cancers such as gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, and other solid tumors.

CEO
Steven L. Hoerter
Employees
350
Headquarters
Waltham, Massachusetts
Founded
2003
Market Cap
2.49B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
288.69K
High Today
$47.54
Low Today
$45.02
Open Price
$47.40
Volume
414.52K
52 Week High
$68.40
52 Week Low
$39.42

DCPH Earnings

-$1.37
-$0.91
-$0.46
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 5, After Hours

You May Also Like

COST
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure